ANDA 90901, held by Jubilant Generics. Pantoprazole Sodium.
As of Nov 16, 2026, ANDA 90901 (Pantoprazole Sodium), held by Jubilant Generics, was first approved by FDA on Aug 30, 2011, with 10 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 30, 2011 | Original application | Approved | None posted |
| Pantoprazole SodiumEQ 20MG BASE · tablet, delayed release;oral | Pantoprazole Sodium | Discontinued |
| Pantoprazole SodiumEQ 40MG BASE · tablet, delayed release;oral | Pantoprazole Sodium | Discontinued |
| Feb 4, 2020 | Supplement 22Labeling · Standard review | Approved | None posted |
| Feb 4, 2020 | Supplement 17Labeling · Standard review | Approved | None posted |
| Feb 4, 2020 | Supplement 15Labeling · Standard review | Approved | None posted |
| Dec 7, 2015 | Supplement 12Labeling · Standard review | Approved | None posted |
| Dec 21, 2014 | Supplement 9Labeling · Standard review | Approved | None posted |
| Dec 21, 2014 | Supplement 8Labeling · Standard review | Approved | None posted |
| May 30, 2013 | Supplement 5Labeling · Standard review | Approved | None posted |
| Oct 16, 2012 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 16, 2012 | Supplement 3Labeling · Standard review | Approved | None posted |
| Oct 16, 2012 | Supplement 2Labeling | Approved | None posted |
| Aug 30, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters